Blockchain Registration Transaction Record

GeoVax's Multi-Antigen COVID Vaccine Shows Superiority in CLL Patients

GeoVax's GEO-CM04S1 COVID-19 vaccine outperforms mRNA vaccines in CLL patients, showing superior immune response in Phase 2 trial, with enrollment now exclusive to its arm.

This development is crucial because immunocompromised individuals, such as those with chronic lymphocytic leukemia (CLL), have been disproportionately affected by COVID-19 due to inadequate protection from existing vaccines. GEO-CM04S1's success could fill a critical gap, offering enhanced immunity and reducing severe outcomes in vulnerable populations. It represents a significant advancement in pandemic preparedness, potentially saving lives and reducing healthcare burdens by addressing a multi-billion-dollar market need for durable, cross-variant protection.